Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: A prospective Trial
🔍 **Clinical Question:**
Is the TULSA-PRO device safe and effective in treating organ-confined low-risk to intermediate-risk prostate cancer (PCa)
💡 **Key Insight:**
After 12 months, 43.5% of patients still had a biopsy-detectable cancerous tumor. However, there was a 40% recurrence-free rate and a 72% treatment-free survival rate at a median follow-up of 37 months.
Urinary and sexual dysfunction was common, with 26% developing stress incontinence, 35% developing overactive bladder, and 54% of potent patients developing erectile dysfunction.
👉 **Why it matters:**
The TULSA-PRO device shows promising results for the focal treatment of localized prostate cancer, although it is not universally curative and was associated with urinary and sexual functional deficits.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.